By Healthcare Edge Editorial Staff Eterna Therapeutics Inc. (Nasdaq: ERNA), a life science company focused on the potential of mRNA cell engineering, said it appointed Dorothy Clarke to its board of directors. Dorothy’s extensive experience will continue to help deliver...

By Tech Edge Editorial Qualtrics, an experience manager provider, said it is offering automated summaries for video feedback, in-depth interviews and focus groups. “The latest Qualtrics announcement is focused on supporting companies in streamlining the often-laborious processes entailed with collecting...

By Tech Edge Editorial Twilio Inc. (NYSE:TWLO) introduced two tools aimed at bolstering transparency and accountability in the use of its AI technology: the CustomerAI Privacy Ladder and AI Nutrition Facts Labels, the company said. The CustomerAI Privacy Ladder categorizes...

By Healthcare Edge Editorial Staff ProSomnus, Inc. (NASDAQ: OSA), a provider of an alternative treatment for Obstructive Sleep Apnea, released new clinical trial data showing that the First Line Obstructive Sleep Apnea Treatment study (FLOSAT) is on track to achieve all...

By Exec Edge Editorial Staff Ventus Therapeutics said it initiated Phase 1 testing for VENT-02, an orally administered NLRP3 inhibitor with remarkable brain penetration. The trial with healthy volunteers aims to explore VENT-02’s impact on neuroinflammatory diseases, such as Parkinson’s...

Sempra Vice President of Investor Relations Glen Donovan By Exec Edge Editorial Sempra (NYSE:SRE), a leading North America energy infrastructure company, recently announced strong second quarter results and a two-for-one stock split – giving greater accessibility to invest in the...

By Daniella Parra Comera Life Sciences Holdings (Nasdaq: CMRA) said it published data showing caffeine’s potential to reduce viscosity in subcutaneous formulations of monoclonal antibodies. The studies demonstrated caffeine’s positive influence on pharmacokinetics and its compatibility with monoclonal antibody ipilimumab,...

By Daniella Parra Avertix Medical said it was collaborating with the Heart & Rhythm Institute of Trinity to bring an FDA-approved implantable heart attack detection and warning system to patients with high-risk coronary disease, it said. The implant, called the...

By Daniella Parra Sparrow Pharmaceuticals said it was extending the trial phase for SPI-62, a potential treatment for ACTH-dependent Cushing’s syndrome. The goal is to gather new long-term safety and tolerability data, with continued monitoring of SPI-62’s effects on signs...

GigaCloud Technology Inc. (Nasdaq: GCT),  said revenue rose 23.5% to $153.1 million in the second quarter – a record for the second straight quarter. The B2B ecommerce solutions company said gross profit was $40.4 million, an increase of 137.1% and...